

silenceworks

BENITEC'S PROGRESS IN SILENCE

Market Snapshot

As at November 12, 2013

Price per share	AUD.600*
Market capitalisation	AUD 51 million
Issued equity: ordinary shares	83,960,907
Options on issue	19,797,734

* Converted to post consolidation pricing

In this issue

- ▶ AGM and Clinical Trial Update
- ▶ Benitec Shareholder Information Sessions
- ▶ Benitec presents at prestigious global liver meeting – AASLD
- ▶ Benitec presents at inaugural Australian Biotech Invest
- ▶ Business and clinical update – five new videos
- ▶ Benitec to present at Three Tickers Twenty Minutes



ddRNAi: Potential for the Health Sector
Professor Geoff McCaughan,
Royal Prince Alfred Hospital

[WATCH THE VIDEO](#)




AGM and Clinical Trial update

Benitec's Chairman, Mr Peter Francis, updated shareholders at the AGM (Melbourne, November 14) with progress of Benitec's first-in-man trial of TT-034 for Hepatitis C, the company's lead drug based on ddRNAi. Mr Francis confirmed that the Investigational New Drug filing with the US FDA was expected to be completed shortly, and that dosing of patients was anticipated early in 2014. [Chairman's address](#) ▶



Shareholder Information Sessions

An informal Shareholder Information Session followed the AGM including a [corporate presentation](#), Q&A with the management team and Board, and networking. A similar session in Sydney the following day (November 15), included an update on the ddRNAi-based HIV program by Calimmune. Dr Geoff Symonds, the CSO, advised that Calimmune had commenced a Phase I/II(a) Clinical Trial in June this year, and that cohort 1 of the trial was nearly fully enrolled.



Benitec presents at prestigious global liver meeting – AASLD

Benitec's SVP of Research & Development, Dr David Suhy, presented to The Liver Meeting® the prestigious conference of the [American Association for the Study of Liver Disorders](#) (Washington, November 1-5). Dr Suhy outlined the mode of action of TT-034, and the design of the upcoming clinical trial and toxicology studies. The Liver Meeting® is the pre-eminent global conference of researchers into liver disease. [Full presentation](#) ▶



Benitec presents at inaugural Australian Biotech Invest

Benitec's CBO, Mr Carl Stubbings, addressed over 300 delegates, mostly qualified investors, at the largest life sciences deal-making conference in Australia, the inaugural [Australia Biotech Invest](#) (Melbourne, October 28-29). Mr Stubbings explained Benitec's unique technology, the size of the target market, and progress with its clinical trial of TT-034 for Hepatitis C, noting the sharp value increase shown by other companies following release of positive clinical data. [Full presentation](#) ▶



Business and clinical update – new videos

In October, Benitec released five short videos – an [investor update](#) from CEO and MD, Dr Peter French, context of its [ddRNAi platform](#) from SVP of Corporate & Business Development, Dr Per Lindell, [the significance of ddRNAi for the health sector](#) from the Head of Liver Transplant, Royal Prince Alfred Hospital, Professor Geoff McCaughan, [progress towards clinical trials](#) of TT-034, Benitec's Hepatitis C drug, from SVP of R&D, Dr David Suhy, plus an [overview](#) of all four videos. [All Benitec videos](#) ▶



Benitec to present at Three Tickers Twenty Minutes in December

On December 5 in Melbourne, Benitec's CEO & MD, Dr Peter French, will present to sector analysts and investors at Buchan Consulting's Three Tickers, Twenty Minutes event. Also presenting will be Osprey Medical (ASX: OSP) and Oncology Research International Limited (ORIL). Benitec investors interested in attending are invited to RSVP by 26 November. [Details & invitation](#) ▶